Transplante médula osea Flashcards

1
Q

Hepatopoietic cell transplantation (HCT) is an advanced therapeutic intervention that is required for a number of malignant and nonmalignant medical conditions.
This procedure typically involves the administration of … followed by … procured from a donor.

A
  • high-dose chemotherapy
  • infusion of hematopoietic stem cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

BONE MARROW MICROENVIRONMENT
… (4)

A
  1. Multipotent CD34+ cells
  2. Different types of cells
  3. Growth factors
  4. Chemokines
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

GOALS OF HCT
To reconstitute a patient’s hematopoietic and immune system by delivering the appropiate amount and type of stem cells.
Generate … effect.
To replace or rectify an underlying deficiency.

A

anti-malignancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

WHERE DO STEM CElLS COME FROM?
1. … : Capable of developing a complete organism. Zygote, early embryo
2. … : Form cells of all germ layers. Early embryo and blastocyte stage
3. … : Seen in specific lineage and found in umbilical cord, fetal and somatic tissue. Hematopoietic, mesenchymal, neuronal

A
  • Totipotent
  • Pluripotent
  • Multipotent
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

COMMON HCT INDICATIONS
Non-malignant
(3) …

A
  1. Aplastic anemia
  2. Hemoglobinopathies
  3. Bone marrow failure syndromes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

¿What are 7 COMMON HCT INDICATIONS?

A
  1. Malignant disease
  2. Leukemia
  3. Lymphoma
  4. Myeloma
  5. Hodgkin’s and NH disease
  6. Myelodisplastic
  7. Solid tumors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

COMMON …
Immunodeficiencies
Autoimmune disease
Inborn error of metabolism
Other

A

HCT INDICATIONS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

HCT PATHWAY
- Planning requires multidisciplinary approach to patient management.
Factors including … (4) need to be considered before decisions regarding the type of transplantation to be performed and medications to be used.

A
  • patient age
  • performance status
  • underlying disease
  • previous complications and donor selection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

HCT PATHWAY
1- Identify: Disease indication, Best donor, Type of transplant, Stem cell source
2- Chemotherapy administration (…), Stem cell procurement (…)
3- … , Hepatopoietic and immune reconstitution

A
  • patient
  • donor
  • Stem cell infusion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

STEM CELL SOURCES
… (2)

A
  1. Bone marrow
  2. Peripheral blood
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

BONE MARROW
1) Soft, sponge-like tissue inside of bones
2) Collected by bone marrow harvest (multiple aspirations of …)

A

posterior iliac crest

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

BONE MARROW
3) Collection goal … /kg cells (… L max)
4) Less graft versus … (not needed in non-malignant disease)

A
  • 2-4 x 10^8
  • 1.5
  • leukemia effect
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

PERIPHERAL BLOOD
1) …% concentration in comparison of bone marrow
2) Requires … and mobilization with medications (…)

A
  • 1
  • bone marrow stimulation
  • filgrastim
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

PERIPHERAL BLOOD
3) Collection goal …/kg cells (… L max)
4) Most commonly used / preferred graft source for …

A
  • 2-6 × 10°6
  • 1.5
  • malignant disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

CORD BLOOD
1) Cells are located in the …
2) Collection at time of delivery of a healthy baby
3) Collection goal … /kg cells (… mL)
4) Needs cryopreservation

A
  • placenta
  • 2.5-3 x 10^7
  • 20-150
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

¿Cuál es el contenido de células madre en la médula ósea, PBSC y sangre de cordón?
Respuesta:

Médula ósea: …
PBSC (sangre periférica): …
Sangre de cordón: … .

A
  • Adecuado.
  • Adecuado
  • Bajo
14
Q

Pregunta: ¿Cómo varía el contenido de células T en estas fuentes?
Respuesta:

Médula ósea: … .
PBSC: …
Sangre de cordón: …

A
  • Bajo
  • Alto
  • Bajo (inmaduras).
15
Q

Pregunta: ¿Qué fuente tiene mayor riesgo de contaminación tumoral en trasplantes autólogos?
Respuesta:
Médula ósea: …
PBSC: …
Sangre de cordón: …

A
  • Alto.
  • Bajo
  • No aplicable.
15
Q

Pregunta: ¿Qué diferencia hay en el emparejamiento de HLA?
Respuesta:

Médula ósea y PBSC: …
Sangre de cordón: …

A
  • Más restrictivo.
  • Menos restrictivo
16
Q

Pregunta: ¿Cuál es el tiempo de injerto según la fuente?
Respuesta:

PBSC: Más rápido (… días).
Médula ósea: Moderado (… días).
Sangre de cordón: Más lento (>…).

A
  • 13-15
    -16-18
  • 3 semanas
17
Q

Pregunta: ¿Cómo varía el riesgo de enfermedad injerto contra huésped (EICH) aguda?
Respuesta:

Médula ósea y PBSC: …
Sangre de cordón: …

A
  • Similar (++).
  • Menor riesgo (+)
18
Q

Pregunta: ¿Qué fuente tiene mayor riesgo de EICH crónica?
Respuesta:

PBSC: …
Médula ósea: …
Sangre de cordón: …

A
  • Mayor (+++).
    -Moderado (++).
  • Menor (+).
19
Q

Pregunta: ¿Qué fuente tiene mayor riesgo de fallo del injerto?
Respuesta:

Sangre de cordón: …
PBSC y médula ósea: …

A
  • Mayor (+++).
  • Similar (++).
20
Q

Pregunta: ¿Cuál es el riesgo de recaída según la fuente?
Respuesta:

Sangre de cordón y PBSC: …
Médula ósea: …

A
  • Mayor (+++).
  • Menor (++).
21
Q

TYPES OF TRANSPLANT
1. … : Patient receives their
own cells
2. … : Patient receives cells from a related or unrelated donor

A
  • Autologous
  • Allogenic
22
Q

TYPES OF ALLOGENIC TRANSPLANT
1. … : twins
2. … : siblings
3. … : parents

A
  • Syngenic
  • Matched family or unrelated
  • Haploidentical
23
Q

HLA AND COMPATIBILITY
The degree of … compatibility is one of the most important factors affecting outcome after HCT.
Initial donor search focuses on identifying a sibling matched at the allele level for HLA-A, B and C loci.

A
  • donor-host Human Leukocyte Antigen (HLA)
24
Q

COMPLICATIONS
1) … : because of the high dose quimiotherapy
2) …
3) …
4) …

A
  • Myelosupression
  • Infection
  • Graft versus host disease
  • Chemo toxicity